Primary sources underpin the regulatory and product-programme statements. Supplier documentation describes published capabilities or terms, not independently audited service performance. URLs are provided below for the research record; inline citations identify their use.
- FDA — GLP-1 compounding policy clarification: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- FDA — Drug Shortages database: https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- Fifth Circuit — Tirzepatide delisting opinion, August 27, 2026: https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
- Fifth Circuit — Semaglutide delisting opinion, revised September 1, 2026: https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- FDA — April 30, 2026 proposed 503B bulks-list exclusions: https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- California Board of Pharmacy — New nonresident-pharmacy requirements: https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
- FDA — DSCSA exemptions: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- FDA — November 9, 2026 GLP-1 safety-labeling communication: https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- FDA — Human Drug Compounding Laws: https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
- FDA — Wholesale-distributor and third-party-logistics reporting: https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
- California Board of Pharmacy — Pharmacy/nonresident-pharmacy licensing: https://www.pharmacy.ca.gov/applicants/phy.shtml
- California Board of Pharmacy — Nonresident sterile-compounding application: https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
- FDA — Registered Outsourcing Facilities: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- FDA — Compounding inspections, recalls and other actions: https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
- FDA — Form 483 frequently asked questions: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- ASHP — Guidelines on Outsourcing Sterile Compounding Services: https://www.ashp.org/-/media/assets/news-and-media/docs/ASHP-Guidelines-on-Outsourcing-Sterile-Compounding-Services.pdf
- FDA — Compounded injectable semaglutide dosing-error alert: https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- HHS — Business Associates FAQs: https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
- HHS OIG — Fraud and Abuse Laws: https://www.oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
- LillyDirect — Patient FAQs: https://www.lilly.com/lillydirect/faq
- NovoCare — Provider home-delivery programme: https://www.novocare.com/hcp/delivery.html
- LillyDirect — Zepbound presentations and published terms: https://www.lilly.com/lillydirect/zepbound
- FDA — Concerns with unapproved GLP-1 drugs: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- Photon — Order Events documentation: https://docs.photon.health/docs/order-events
- Photon — Webhooks documentation: https://docs.photon.health/docs/webhooks
- ASHP — Outsourcing Sterile Products Vendor Assessment Tool: https://outsourcing.ashp.org/
- FDA — Compounding questions and answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Sources cited on this page
- fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- accessdata.fda.gov · Source 2 ↗https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
- govinfo.gov · Source 3 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
- ca5.uscourts.gov · Source 4 ↗https://www.ca5.uscourts.gov/opinions/unpub/25/25-10758.0.pdf
- fda.gov · Source 5 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- pharmacy.ca.gov · Source 6 ↗https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
- fda.gov · Source 7 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
- fda.gov · Source 8 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential
- fda.gov · Source 9 ↗https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws
- fda.gov · Source 10 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/annual-licensure-reporting-wholesale-drug-distributors-and-third-party-logistics-providers
- pharmacy.ca.gov · Source 11 ↗https://www.pharmacy.ca.gov/applicants/phy.shtml
- pharmacy.ca.gov · Source 12 ↗https://www.pharmacy.ca.gov/forms/nrp_comp_app_pkt.pdf
- fda.gov · Source 13 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- fda.gov · Source 14 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
- fda.gov · Source 15 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- ashp.org · Source 16 ↗https://www.ashp.org/-/media/assets/news-and-media/docs/ASHP-Guidelines-on-Outsourcing-Sterile-Compounding-Services.pdf
- fda.gov · Source 17 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- hhs.gov · Source 18 ↗https://www.hhs.gov/hipaa/for-professionals/privacy/guidance/business-associates/index.html
- oig.hhs.gov · Source 19 ↗https://www.oig.hhs.gov/compliance/physician-education/fraud-abuse-laws/
- lilly.com · Source 20 ↗https://www.lilly.com/lillydirect/faq
- novocare.com · Source 21 ↗https://www.novocare.com/hcp/delivery.html
- lilly.com · Source 22 ↗https://www.lilly.com/lillydirect/zepbound
- fda.gov · Source 23 ↗https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- docs.photon.health · Source 24 ↗https://docs.photon.health/docs/order-events
- docs.photon.health · Source 25 ↗https://docs.photon.health/docs/webhooks
- outsourcing.ashp.org · Source 26 ↗https://outsourcing.ashp.org/
- fda.gov · Source 27 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers